The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies
Abstract
Colistin is the last resort for treatment of multidrug-resistant Acinetobacter baumannii. Unfortunately, resistance to colistin has been reported all over the world. The highest resistance rate was reported in Asia, followed by Europe. The heteroresistance rate of A. baumannii to colistin is generally higher than the resistance rate. The mechanism of resistance might be loss of lipopolysaccharide or/and the PmrAB two-component system. Pharmacokinetic/pharmacodynamic studies revealed that colistin monotherapy is unable to prevent resistance, and combination therapy might be the best antimicrobial strategy against colistin-resistant A. baumannii. Colistin/rifampicin and colistin/carbapenem are the most studied combinations that showed promising results in vitro, in vivo and in the clinic. New peptides showing good activity against colistin-resistant A. baumannii are also being investigated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., & Bartlett, J. (2009) · Clinical Infectious Diseases · doi:10.1086/595011 · Cited by 4,958
Raetz, C. R. H., & Whitfield, C. (2002) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.71.110601.135414 · Cited by 4,404
Falagas, M. E., Kasiakou, S. K., & Saravolatz, L. D. (2005) · Clinical Infectious Diseases · doi:10.1086/429323 · Cited by 1,744
Hancock, R. E. (1997) · The Lancet · doi:10.1016/s0140-6736(97)80051-7 · Cited by 1,096
Toxicity of polymyxins: a systematic review of the evidence from old and recent studies
Falagas, M. E., & Kasiakou, S. K. (2006) · Critical Care · doi:10.1186/cc3995 · Cited by 828
Moffatt, J. H., Harper, M., Harrison, P., Hale, J. D. F., Vinogradov, E., Seemann, T., Henry, R., Crane, B., St. Michael, F., Cox, A. D., et al. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00834-10 · Cited by 812
Garonzik, S. M., Li, J., Thamlikitkul, V., Paterson, D. L., Shoham, S., Jacob, J., Silveira, F. P., Forrest, A., & Nation, R. L. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01733-10 · Cited by 696
Heteroresistance to Colistin in Multidrug-Resistant Acinetobacter baumannii
Li, J., Rayner, C. R., Nation, R. L., Owen, R. J., Spelman, D., Tan, K. E., & Liolios, L. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00103-06 · Cited by 548
Plachouras, D., Karvanen, M., Friberg, L. E., Papadomichelakis, E., Antoniadou, A., Tsangaris, I., Karaiskos, I., Poulakou, G., Kontopidou, F., Armaganidis, A., et al. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01361-08 · Cited by 494
Adams, M. D., Nickel, G. C., Bajaksouzian, S., Lavender, H., Murthy, A. R., Jacobs, M. R., & Bonomo, R. A. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00284-09 · Cited by 448
Cited by
Molecular mechanisms of antibiotic resistance
Blair, J. M. A., Webber, M. A., Baylay, A. J., Ogbolu, D. O., & Piddock, L. J. V. (2015) · Nature Reviews Microbiology · doi:10.1038/nrmicro3380 · Cited by 4,092
Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria
Olaitan, A. O., Morand, S., & Rolain, J.-M. (2014) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00643 · Cited by 1,395
Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges
Wong, D., Nielsen, T. B., Bonomo, R. A., Pantapalangkoor, P., Luna, B., & Spellberg, B. (2017) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-16 · Cited by 1,170
Lee, C.-R., Lee, J. H., Park, M., Park, K. S., Bae, I. K., Kim, Y. B., Cha, C.-J., Jeong, B. C., & Lee, S. H. (2017) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2017.00055 · Cited by 1,016
Acinetobacter baumannii: evolution of a global pathogen
Antunes, L. C. S., Visca, P., & Towner, K. J. (2014) · Pathogens and Disease · doi:10.1111/2049-632x.12125 · Cited by 925
Update on the antibiotic resistance crisis
Rossolini, G. M., Arena, F., Pecile, P., & Pollini, S. (2014) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.09.006 · Cited by 695
Mechanisms and clinical relevance of bacterial heteroresistance
Andersson, D. I., Nicoloff, H., & Hjort, K. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0218-1 · Cited by 513
Mechanisms of antimicrobial resistance in Gram-negative bacilli
Ruppé, É., Woerther, P.-L., & Barbier, F. (2015) · Annals of Intensive Care · doi:10.1186/s13613-015-0061-0 · Cited by 490
World Health Organization Report: Current Crisis of Antibiotic Resistance
Talebi Bezmin Abadi, A., Rizvanov, A. A., Haertlé, T., & Blatt, N. L. (2019) · BioNanoScience · doi:10.1007/s12668-019-00658-4 · Cited by 465
Resistance to polymyxins in Gram-negative organisms
Jeannot, K., Bolard, A., & Plésiat, P. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.11.029 · Cited by 402
Nicoloff, H., Hjort, K., Levin, B. R., & Andersson, D. I. (2019) · Nature Microbiology · doi:10.1038/s41564-018-0342-0 · Cited by 401
Antimicrobial resistance in Acinetobacter baumannii: From bench to bedside
Lin, M.-F. (2014) · World Journal of Clinical Cases · doi:10.12998/wjcc.v2.i12.787 · Cited by 357
Tackling Threats and Future Problems of Multidrug-Resistant Bacteria
Medina, E., & Pieper, D. H. (2016) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2016_492 · Cited by 356
Asif, M., Alvi, I. A., & Rehman, S. U. (2018) · Infection and Drug Resistance · doi:10.2147/idr.s166750 · Cited by 333
Acinetobacter baumannii: Evolution of Antimicrobial Resistance—Treatment Options
Murray, G., Peleg, A., & Doi, Y. (2015) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0034-1398388 · Cited by 316
Cerceo, E., Deitelzweig, S. B., Sherman, B. M., & Amin, A. N. (2016) · Microbial Drug Resistance · doi:10.1089/mdr.2015.0220 · Cited by 313
Acinetobacter baumannii Resistance: A Real Challenge for Clinicians
Vázquez-López, R., Solano-Gálvez, S. G., Juárez Vignon-Whaley, J. J., Abello Vaamonde, J. A., Padró Alonzo, L. A., Rivera Reséndiz, A., Muleiro Álvarez, M., Vega López, E. N., Franyuti-Kelly, G., Álvarez-Hernández, D. A., et al. (2020) · Antibiotics · doi:10.3390/antibiotics9040205 · Cited by 296
New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections
Isler, B., Doi, Y., Bonomo, R. A., & Paterson, D. L. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01110-18 · Cited by 293
A new strategy to fight antimicrobial resistance: the revival of old antibiotics
Cassir, N., Rolain, J.-M., & Brouqui, P. (2014) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00551 · Cited by 280
Kon, H., Hameir, A., Nutman, A., Temkin, E., Keren Paz, A., Lellouche, J., Schwartz, D., Weiss, D. S., Kaye, K. S., Daikos, G. L., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.05093-22 · Cited by 35
“While the PAP assay is the gold standard for HR determination, some studies applied other methods, such as agar screen and Etest (17, 28).”
MethodAcar, M. B., Ayaz-Güner, Ş., Güner, H., Dinç, G., Ulu Kılıç, A., Doğanay, M., & Özcan, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1001633 · Cited by 8
Metadata
- Authors
- Cai, Y., Chai, D., Wang, R., Liang, B., & Bai, N.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-03-22
- Volume
- 67
- Issue
- 7
- Pages
- 1607-1615
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2161069049
- Cited by
- 557
- References
- 52
- FWCI
- 17.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.